Role of dopamine and clinical heterogeneity in cognitive dysfunction in Parkinson's disease

Prog Brain Res. 2022;269(1):309-343. doi: 10.1016/bs.pbr.2022.01.012. Epub 2022 Feb 9.

Abstract

Parkinson's disease (PD) is commonly treated with dopaminergic medication, which enhances some, while impairing other cognitive functions. It can even contribute to impulse control disorder and addiction. We describe the history of research supporting the dopamine overdose hypothesis, which accounts for the large within-patient variability in dopaminergic medication effects across different tasks by referring to the spatially non-uniform pattern of dopamine depletion in dorsal versus ventral striatum. However, there is tremendous variability in dopaminergic medication effects not just within patients across distinct tasks, but also across different patients. In the second part of this chapter we review recent studies addressing the large individual variability in the negative side effects of dopaminergic medication on functions that implicate dopamine, such as value-based learning and choice. These studies begin to unravel the mechanisms of dopamine overdosing, thus revising the strict version of the overdose hypothesis. For example, the work shows that the canonical boosting of reward-versus punishment-based choice by medication is greater in patients with depression and a non-tremor phenotype, which both implicate, among other pathology, more rather than less severe dysregulation of the mesolimbic dopamine system. Future longitudinal cohort studies are needed to identify how to optimally combine different clinical, personality, cognitive, neural, genetic and molecular predictors of detrimental medication effects in order to account for as much of the relevant variability as possible. This will provide a useful tool for precision neurology, allowing individual and contextual tailoring of (the dose of) dopaminergic medication in order to maximize its cognitive benefits, yet minimize its side effects.

Keywords: Cognitive dysfunction; Decision making; Depression; Dopaminergic medication; Gambling; Heterogeneity; Impulse control disorder; Overdose hypothesis; Parkinson's disease; Prefrontal cortex; Reinforcement learning; Side effects; Striatum; Tremor phenotype.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cognitive Dysfunction* / drug therapy
  • Cognitive Dysfunction* / etiology
  • Dopamine
  • Dopamine Agents / adverse effects
  • Humans
  • Parkinson Disease* / complications
  • Parkinson Disease* / drug therapy
  • Reward

Substances

  • Dopamine Agents
  • Dopamine